SCHEDULE 13G/A: BlackRock Boosts Stake in Blueprint Medicines Corp to 8.0%
Beneficial Ownership Report
BlackRock, Inc. has disclosed an increased passive ownership stake of 8.0% in Blueprint Medicines Corp, holding over 5 million shares as of March 31, 2025.
Summary
- BlackRock, Inc. has filed an Amendment No. 10 to Schedule 13G, reporting its beneficial ownership in Blueprint Medicines Corp.
- As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 5,090,723 shares of Blueprint Medicines Corp's Common Stock.
- This ownership represents 8.0% of the total outstanding class of securities.
- BlackRock, Inc. holds sole voting power over 5,018,191 shares and sole dispositive power over 5,090,723 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Various BlackRock subsidiaries and affiliates contribute to this aggregate ownership, with BlackRock Investment Management, LLC specifically noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as a significant increase in institutional ownership by a major firm like BlackRock can be interpreted as a vote of confidence in the company, even if the filing itself is purely factual and passive.
Positives
- BlackRock, a major institutional investor, increasing its stake to 8.0% could signal confidence in Blueprint Medicines Corp's long-term prospects and stability.
- The filing confirms BlackRock's passive investment intent, indicating no immediate plans to influence the company's control or operations.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view BlackRock's increased stake as a positive signal, potentially boosting investor confidence in Blueprint Medicines Corp.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which required the filing of this statement (ownership threshold crossed). |
| 04/23/2025 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Blueprint Medicines Corp, Schedule 13G, Institutional Ownership, Common Stock, Passive Investment, Biotechnology, Pharmaceuticals, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.